金斯瑞生物科技(01548)：传奇宣布于2025年ASH年会上公布报告

Core Viewpoint - Legend Biotech announced the presentation of long-term follow-up clinical and translational research data for CARVYKTI (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1: Clinical Research Findings - The CARTITUDE-1 and CARTITUDE-4 studies provided significant data on the efficacy of CARVYKTI in RRMM patients [1] - The latest results from the Phase III study CARTITUDE-4 were also presented, highlighting the ongoing research into the treatment's effectiveness [1] - Six posters were showcased, demonstrating the durability of response data for CARVYKTI across different subgroups and real-world studies [1] Group 2: New Product Development - Legend Biotech presented initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D at the ASH annual meeting [1]